Yeheng Zhu

7534763, May 19, 2009

Nov 8, 2006

11/594531

Feng Qian - Hillsborough NJ, US
William R. Ewing - Yardley PA, US
Claudio Mapelli - Plainsboro NJ, US
Douglas James Riexinger - Flemington NJ, US
Ving G. Lee - Hamilton NJ, US
Richard B. Sulsky - West Trenton NJ, US
Yeheng Zhu - Stockton NJ, US
Tasir Shamsul Haque - Yardley PA, US
Rogelio L. Martinez - Monmouth Junction NJ, US
Vijay Naringrekar - Princeton NJ, US
Nina Ni - Kendall Park NJ, US
Lori S. Burton - Robbinsville NJ, US

Bristol-Myers Squibb Company - Princeton NJ

A61K 38/00
C07K 2/00

514 2, 530300

The present invention provides novel pharmaceutical compositions comprising a human glucagon-like peptide-1 (GLP-1)-receptor modulator as an active ingredient in a sustained release formulation.

7629342, Dec 8, 2009

Jun 16, 2006

11/454324

William R. Ewing - Yardley PA, US
Yeheng Zhu - Stockton NJ, US
Bruce A. Ellsworth - Princeton NJ, US

Bristol-Myers Squibb Company - Princeton NJ

C07D 487/04
A61K 31/503

51425201, 544236

The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the general Formula I and Formula II:.

7960349, Jun 14, 2011

May 25, 2007

11/753616

William R. Ewing - Yardley PA, US
Claudio Mapelli - Plainsboro NJ, US
Douglas James Riexinger - Flemington NJ, US
Ving G. Lee - Hamilton NJ, US
Richard B. Sulsky - West Trenton NJ, US
Yeheng Zhu - Stockton NJ, US

Bristol-Myers Squibb Company - Princeton NJ

A61K 38/08
A61K 38/00

514 218, 514 11, 530330

The subject matter described herein provides novel human glucagon-like peptide-1 (GLP-1) receptor modulators that have biological activity similar or superior to native GLP-1 peptide and thus are useful for the treatment or prevention of diseases or disorders associated with GLP activity. The described compounds include chemically modified peptides that may stimulate insulin secretion in type II diabetics, but also produce other beneficial insulinotropic responses. These synthetic peptide GLP-1 receptor modulators exhibit increased stability to proteolytic cleavage making them ideal therapeutic candidates for oral or parenteral administration. The disclosed and claimed peptides show desirable pharmacokinetic properties and desirable potency in efficacy models of diabetes.

8030306, Oct 4, 2011

Dec 13, 2007

12/518707

William R. Ewing - Yardley PA, US
Yeheng Zhu - Stockton NJ, US
Richard B. Sulsky - West Trenton NJ, US

Bristol-Myers Squibb Company - Princeton NJ

C07D 487/04
A61K 31/5025
A61P 3/00

514248, 544236

The present application describes CB-1 inverse agonists according to Formula (I) and (Ia), pharmaceutical compositions comprising at least one compound according to Formula (I) or (Ia), and optionally one or more additional therapeutic agents and methods of treatment using the compounds according to Formula (I) or (Ia), both alone and in combination with one or more additional therapeutic agents. The preferred compounds have the general Formula (Ia), including all prodrugs, pharmaceutically acceptable salts and stereoisomer, thereof, wherein R, R, Ar, Arare defined herein.

7361766, Apr 22, 2008

Jan 12, 2006

11/330656

Chongqing Sun - East Windsor NJ, US
William R. Ewing - Yardley PA, US
Yanting Huang - Pennington NJ, US
Yeheng Zhu - Stockton NJ, US

Bristol-Myers Squibb Company - Princeton NJ

C07D 471/02

546122

The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the general Formula I:.

20060287242, Dec 21, 2006

Jun 30, 2005

11/170968

William Ewing - Yardley PA, US
Claudio Mapelli - Plainsboro NJ, US
Richard Sulsky - West Trenton NJ, US
Tasir Haque - Yardley PA, US
Ving Lee - Hamilton NJ, US
Douglas Riexinger - Flemington NJ, US
Rogelio Martinez - Monmouth NJ, US
Yeheng Zhu - Stockton NJ, US

A61K 38/10
C07K 7/08

514015000, 530328000

The present invention provides novel human glucagon-like peptide-1 (GLP-1)-receptor modulators that have biological activity similar or superior to native GLP-1 peptide and thus are useful for the treatment or prevention of diseases or disorders associated with GLP activity. Further, the present invention provides novel, chemically modified peptides that not only stimulate insulin secretion in type II diabetics, but also produce other beneficial insulinotropic responses. These synthetic peptide GLP-1 receptor modulators exhibit increased stability to proteolytic cleavage making them ideal therapeutic candidates for oral or parenteral administration. The peptides of this invention show desirable pharmacokinetic properties and desirable potency in efficacy models of diabetes.

20070021346, Jan 25, 2007

May 26, 2006

11/442017

William Ewing - Yardley PA, US
Claudio Mapelli - Plainsboro NJ, US
Douglas Riexinger - Flemington NJ, US
Ving Lee - Hamilton NJ, US
Richard Sulsky - West Trenton NJ, US
Yeheng Zhu - Stockton NJ, US

A61K 38/10
C07K 7/08

514015000, 530328000

The subject matter described herein provides novel human glucagon-like peptide-1 (GLP-1) receptor modulators that have biological activity similar or superior to native GLP-1 peptide and thus are useful for the treatment or prevention of diseases or disorders associated with GLP activity. The described compounds include chemically modified peptides that not only stimulate insulin secretion in type II diabetics, but also produce other beneficial insulinotropic responses. These synthetic peptide GLP-1 receptor modulators exhibit increased stability to proteolytic cleavage making them ideal therapeutic candidates for oral or parenteral administration. The disclosed and claimed peptides show desirable pharmacokinetic properties and desirable potency in efficacy models of diabetes.

20070238669, Oct 11, 2007

Jan 11, 2007

11/622142

Tasir Haque - Yardley PA, US
William Ewing - Yardley PA, US
Claudio Mapelli - Plainsboro NJ, US
Ving Lee - Hamilton NJ, US
Richard Sulsky - West Trenton NJ, US
Douglas Riexinger - Flemington NJ, US
Rogelio Martinez - Monmouth Junction NJ, US
Yeheng Zhu - Stockton NJ, US
Zheming Ruan - Dayton NJ, US

A61K 38/00
C07C 233/00
C07C 321/00
C07K 7/00

514015000, 530327000, 564162000, 564163000

The present invention provides novel human glucagon-like peptide-1 (GLP-1)-receptor modulators that have biological activity similar or superior to native GLP-1 peptide and thus are useful for the treatment or prevention of diseases or disorders associated with GLP activity. Further, the present invention provides novel, chemically modified compounds that not only stimulate insulin secretion in type II diabetics, but also produce other beneficial insulinotropic responses. These synthetic peptide GLP-1 receptor modulators exhibit increased stability to proteolytic cleavage making them ideal therapeutic candidates for oral or parenteral administration. The compounds of this invention show desirable pharmacokinetic properties and desirable potency in efficacy models of diabetes.